O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study

Publication | Open Access

DOI Full Paper Access

Citations

References

2023

Year

Elizabeth Smyth, M. Mauer, Chiara Alessandra Cella, Irit Ben‐Aharon, Guillaume Piessen, Lucjan Wyrwicz, Ghazwan Al-Haidari, Tania Fleitas, Valérie Boige, M. Stahl,

Annals of Oncology

O-6 Eortc 1707Surgical OncologyEsophageal CancerGastrointestinal OncologyAdjuvant ImmunotherapyMedicineGastroenterologyPathologySurgeryCancer TreatmentImmunotherapyOncologyRadiation OncologyHigh Risk